HighTower Advisors LLC Purchases 2,060 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

HighTower Advisors LLC lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 37.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,594 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,060 shares during the period. HighTower Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $851,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Cinctive Capital Management LP bought a new stake in Jazz Pharmaceuticals during the third quarter worth $14,277,000. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Jazz Pharmaceuticals by 46.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 14,593 shares of the specialty pharmaceutical company’s stock worth $1,626,000 after buying an additional 4,627 shares during the last quarter. ARGA Investment Management LP boosted its stake in Jazz Pharmaceuticals by 83.9% in the third quarter. ARGA Investment Management LP now owns 12,195 shares of the specialty pharmaceutical company’s stock valued at $1,359,000 after buying an additional 5,562 shares in the last quarter. Captrust Financial Advisors grew its position in Jazz Pharmaceuticals by 9.5% in the third quarter. Captrust Financial Advisors now owns 4,965 shares of the specialty pharmaceutical company’s stock valued at $553,000 after acquiring an additional 430 shares during the last quarter. Finally, Capstone Investment Advisors LLC acquired a new position in Jazz Pharmaceuticals during the third quarter worth about $327,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Piper Sandler restated an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $177.00.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock valued at $816,289 over the last quarter. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.6 %

Jazz Pharmaceuticals stock opened at $121.74 on Thursday. The firm has a 50 day moving average price of $118.02 and a two-hundred day moving average price of $112.48. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The firm has a market cap of $7.36 billion, a price-to-earnings ratio of 17.15, a PEG ratio of 1.02 and a beta of 0.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.